Theriva Biologics Advances VCN-01 Into Pivotal Phase 3

An announcement from Theriva Biologics ( (TOVX) ) is now available.

On March 23, 2026, Theriva Biologics reported that a recent Type B End-of-Phase 2 meeting with the U.S. Food and Drug Administration yielded broad agreement on the design of a pivotal Phase 3 trial of VCN-01 plus gemcitabine/nab-paclitaxel for first-line treatment of metastatic pancreatic ductal adenocarcinoma. The planned study will mirror the successful VIRAGE Phase 2 trial, whose 2025 data showed improved overall survival, progression-free survival and duration of response versus standard chemotherapy alone, with stronger benefits in patients receiving two VCN-01 doses.

The FDA endorsed key elements such as repeat dosing in macrocycles, inclusion and exclusion criteria, overall survival as the primary endpoint, progression-free survival as a key secondary endpoint and the use of an adaptive design with predefined interim analyses. Combined with earlier guidance from the European Medicines Agency’s CHMP, this regulatory alignment positions Theriva to finalize a single, high-quality randomized, double-blind Phase 3 protocol that could, if successful, support a biologics license application and underpins the company’s efforts to secure development funding and partnerships around VCN-01 in metastatic PDAC.

The most recent analyst rating on (TOVX) stock is a Hold with a $0.19 price target. To see the full list of analyst forecasts on Theriva Biologics stock, see the TOVX Stock Forecast page.

Spark’s Take on TOVX Stock

According to Spark, TipRanks’ AI Analyst, TOVX is a Neutral.

The score is primarily held down by weak financial performance (no revenue, ongoing losses, and sustained cash burn with a shrinking equity base). Technicals also remain weak over longer timeframes, with only neutral near-term momentum. Corporate events provide some upside via regulatory support and pipeline focus, but do not fully offset the funding/dilution overhang implied by the company’s financial profile and warrant-related uncertainty.

To see Spark’s full report on TOVX stock, click here.

More about Theriva Biologics

Theriva Biologics, Inc. is a diversified clinical-stage biotechnology company focused on developing therapeutics to treat cancer and related diseases in areas of high unmet need. Its lead asset is VCN-01, an intravenously and locally deliverable oncolytic adenovirus designed to replicate selectively in tumor cells and degrade tumor stroma, alongside an exploratory program, SYN-004, targeting prevention of microbiome damage and graft-versus-host disease in transplant patients.

Average Trading Volume: 10,252,036

Technical Sentiment Signal: Strong Sell

Current Market Cap: $8.89M

See more insights into TOVX stock on TipRanks’ Stock Analysis page.